ImmuPharma plc (USD) ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodulator, is presently in Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disorder. Additional product developments include BioAMB, a peptide-based medication for fungal infections, particularly those caused by the aspergillus family, and BioCin, a peptide-derived antibacterial agent designated for high medical need and as a last-resort treatment option. ImmuPharma also maintains a partnership with the Centre National de la Recherche Scientifique (CNRS) to develop a peptide technology platform aimed at diabetes, specifically involving GLP-1 agonists and glucagon antagonists for both Type I and Type II diabetes. Furthermore, the company has a licensing and development agreement in place with Avion Pharmaceuticals LLC.

ImmuPharma plc (USD) Passive

1 Bartholomew Close, London, GB, EC1A 7BL

Stock Price USD

Price Change

Last Dividend USD

IMMPF's stock peer is ACOGF (Alpha Cognition Inc.)

IMMPF's stock peer is CHBRF (Chill Brands Group PLC)

IMMPF's stock peer is DMTTF (Small Pharma Inc.)

IMMPF's stock peer is EMMLF (OKYO Pharma Limited)

IMMPF's stock peer is GENH (Generation Hemp, Inc.)

IMMPF's stock peer is IBXNF (IBEX Technologies Inc.)

IMMPF's stock peer is IGXT (IntelGenx Technologies Corp.)

IMMPF's stock peer is KMSTF (Kadimastem Ltd)

IMMPF's stock peer is LSBCF (LakeShore Biopharma Co., Ltd)

IMMPF's stock peer is OCEL (Organicell Regenerative Medicine, Inc.)

Healthcare Biotechnology

ImmuPharma plc, established in London, United Kingdom, in 1999, is a biopharmaceutical company dedicated to discovering and advancing peptide-based therapeutics. These treatments are focused on tackling conditions related to autoimmunity, inflammation, and various infections. The company's primary drug candidate, Lupuzor, an autophagy immunomodulator, is presently in Phase III clinical trials for the management of lupus, a chronic autoimmune inflammatory disorder. Additional product developments include BioAMB, a peptide-based medication for fungal infections, particularly those caused by the aspergillus family, and BioCin, a peptide-derived antibacterial agent designated for high medical need and as a last-resort treatment option. ImmuPharma also maintains a partnership with the Centre National de la Recherche Scientifique (CNRS) to develop a peptide technology platform aimed at diabetes, specifically involving GLP-1 agonists and glucagon antagonists for both Type I and Type II diabetes. Furthermore, the company has a licensing and development agreement in place with Avion Pharmaceuticals LLC.

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
		3.00	0.00 %	Special

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions